Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093444 · ClinicalTrials.gov registry record · Phase 1
Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors
A Phase 1 study of Metastatic Cancer and Liver Cancer, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00093444: Completed Phase 1 study of Metastatic Cancer and Liver Cancer, sponsored by National Institutes of Health Clinical Center (CC).
NCT00093444 is a Phase 1 study of Metastatic Cancer and Liver Cancer that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 30 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093444, a Phase 1 study of Metastatic Cancer and Liver Cancer, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with liposomal doxorubicin may increase the effectiveness of the drug and kill more tumor cells. PURPOSE: This phase I trial is studying the best dose of liposomal doxorubicin when given with radiofrequency ablation in treating patients with primary or metastatic liver tumors.
Conditions Studied
Interventions
- DRUG lyso-thermosensitive liposomal doxorubicin
- PROCEDURE radiofrequency ablation
Study Locations (2)
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office - Bethesda
Other
- Queen Mary Hospital - Hong Kong - Hong Kong
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-09 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
What the finished NCT00093444 record still lists
NCT00093444 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which lyso-thermosensitive liposomal doxorubicin is the first listed.
NCT00093444 reports a single indexed study location in Maryland, Other.
Frequently Asked Questions
What is clinical trial NCT00093444 about?
NCT00093444 is a clinical study titled "Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors". RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with liposomal doxorubicin m...
What is the current status of trial NCT00093444?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2004-09. Estimated completion is 2010-01.
What conditions does trial NCT00093444 study?
This clinical trial studies the following conditions: Metastatic Cancer, Liver Cancer.
What interventions are being tested in trial NCT00093444?
The interventions under investigation include: lyso-thermosensitive liposomal doxorubicin (DRUG), radiofrequency ablation (PROCEDURE).
Who is sponsoring clinical trial NCT00093444?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00093444 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00093444's enrollment target sits among peer trials
30 80th of 109 higher than 27 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia